Annual report
7745.TEDINET S100OHD5
Period2021-04-01 → 2022-03-31
Filed2022-06-27
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 158
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥51.7bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales |
| Revenue | ¥48.4bn | 2020-04-01 → 2021-03-31 | Cons. | Net sales |
| Revenue | ¥49.2bn | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥48.3bn | 2018-04-01 → 2019-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥44.1bn | 2017-04-01 → 2018-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥5.5bn | 2021-04-01 → 2022-03-31 | Cons. | Operating income |
| Operating income | ¥4.4bn | 2020-04-01 → 2021-03-31 | Cons. | Operating income |
| Ordinary income | ¥5.6bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥4.6bn | 2020-04-01 → 2021-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥3.4bn | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.7bn | 2018-04-01 → 2019-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.3bn | 2017-04-01 → 2018-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥5.5bn | 2021-04-01 → 2022-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥4.5bn | 2020-04-01 → 2021-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥3.6bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥3.3bn | 2020-04-01 → 2021-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.6bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.9bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.8bn | 2017-04-01 → 2018-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥4.0bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss |
| Net income | ¥3.6bn | 2020-04-01 → 2021-03-31 | Cons. | Profit loss |
| Total assets | ¥59.2bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥54.1bn | at 2021-03-31 | Cons. | Assets |
| Total assets | ¥49.3bn | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥51.0bn | at 2019-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥47.0bn | at 2018-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥32.2bn | at 2022-03-31 | Cons. | Liabilities |
| Total liabilities | ¥30.7bn | at 2021-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥27.0bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥23.4bn | at 2021-03-31 | Cons. | Net assets |
| Net assets / equity | ¥18.6bn | at 2020-03-31d | Cons. | Net assets |
| Net assets / equity | ¥18.1bn | at 2019-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥15.9bn | at 2018-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥11.9bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥13.1bn | at 2021-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥11.0bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥12.1bn | at 2021-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥9.1bn | at 2020-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥7.5bn | at 2019-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥7.2bn | at 2018-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥1.8bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥5.2bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥4.3bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥2.2bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥4.1bn | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥2.4bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥2.2bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.1bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.5bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.5bn | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥741m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥257m | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.3bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥329m | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.4bn | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥172.92 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥161.87 | 2020-04-01 → 2021-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥76.88 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥92.74 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥89.22 | 2017-04-01 → 2018-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥172.66 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥161.5 | 2020-04-01 → 2021-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥73.53 | 2019-04-01 → 2020-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥92.36 | 2018-04-01 → 2019-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥89.01 | 2017-04-01 → 2018-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥1,167.95 | at 2022-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,007.01 | at 2021-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥833.97 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥836.13 | at 2019-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥771.84 | at 2018-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 40.8% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 38.4% | at 2021-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.9% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.6% | at 2019-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.6% | at 2018-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 15.9% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 17.6% | 2020-04-01 → 2021-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 9.2% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 11.5% | 2018-04-01 → 2019-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 12.0% | 2017-04-01 → 2018-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 2,591 | at 2022-03-31 | Cons. | Number of employees |
| Employees | 2,544 | at 2021-03-31 | Cons. | Number of employees |
| Employees | 2,633 | at 2020-03-31d | Cons. | Number of employees |
| Employees | 2,697 | at 2019-03-31d | Cons. | Number of employees |
| Employees | 2,557 | at 2018-03-31d | Cons. | Number of employees |
| Revenue | ¥35.0bn | 2021-04-01 → 2022-03-31 | Standalone | Net sales |
| Revenue | ¥33.1bn | 2020-04-01 → 2021-03-31 | Standalone | Net sales |
| Revenue | ¥31.5bn | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥33.7bn | 2018-04-01 → 2019-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥30.7bn | 2017-04-01 → 2018-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥2.2bn | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Operating income | ¥2.0bn | 2020-04-01 → 2021-03-31 | Standalone | Operating income |
| Ordinary income | ¥2.6bn | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥2.7bn | 2020-04-01 → 2021-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥834m | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.6bn | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥938m | 2017-04-01 → 2018-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥2.6bn | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥2.7bn | 2020-04-01 → 2021-03-31 | Standalone | Income before income taxes |
| Net income | ¥2.0bn | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | ¥2.1bn | 2020-04-01 → 2021-03-31 | Standalone | Profit loss |
| Net income | ¥658m | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥1.3bn | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥832m | 2017-04-01 → 2018-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥39.6bn | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥38.9bn | at 2021-03-31 | Standalone | Assets |
| Total assets | ¥36.9bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥39.2bn | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥38.1bn | at 2018-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥21.0bn | at 2022-03-31 | Standalone | Liabilities |
| Total liabilities | ¥21.7bn | at 2021-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥18.6bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥17.2bn | at 2021-03-31 | Standalone | Net assets |
| Net assets / equity | ¥15.5bn | at 2020-03-31d | Standalone | Net assets |
| Net assets / equity | ¥15.2bn | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥14.1bn | at 2018-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥4.5bn | at 2022-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥4.0bn | at 2021-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥95.62 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥101.03 | 2020-04-01 → 2021-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥32.1 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥64.93 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥40.64 | 2017-04-01 → 2018-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥95.48 | 2021-04-01 → 2022-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥100.8 | 2020-04-01 → 2021-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥30.7 | 2019-04-01 → 2020-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥64.66 | 2018-04-01 → 2019-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥40.55 | 2017-04-01 → 2018-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥25 | 2021-04-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥25 | 2020-04-01 → 2021-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥20 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥17 | 2018-04-01 → 2019-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥12 | 2017-04-01 → 2018-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥897.51 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥833.78 | at 2021-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥752.41 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥739.86 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥689.35 | at 2018-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 46.9% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 44.2% | at 2021-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 42.1% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 38.6% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 37.1% | at 2018-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 11.1% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 12.7% | 2020-04-01 → 2021-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.3% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 9.1% | 2018-04-01 → 2019-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.0% | 2017-04-01 → 2018-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 22,601,000 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 22,579,000 | at 2021-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 22,579,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 22,579,000 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 22,579,000 | at 2018-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 743 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 732 | at 2021-03-31 | Standalone | Number of employees |
| Employees | 716 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 708 | at 2019-03-31d | Standalone | Number of employees |
| Employees | 696 | at 2018-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 156
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2021-04-01 → 2022-03-31 | ¥49m |
| Reconciling Itemsreconciling | depreciation | 2021-04-01 → 2022-03-31 | ¥53m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2022-03-31 | −¥23.4bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2022-03-31 | −¥23.4bn |
| Reconciling Itemsreconciling | segment assets | at 2022-03-31 | −¥9.6bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2022-03-31 | −¥2.0bn |
| America Measuring Instrumentsreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥14m |
| America Measuring Instrumentsreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥40m |
| America Measuring Instrumentsreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥4.0bn |
| America Measuring Instrumentsreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥3.7bn |
| America Measuring Instrumentsreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥240m |
| America Measuring Instrumentsreportable segment | segment assets | at 2022-03-31 | ¥3.4bn |
| America Measuring Instrumentsreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥318m |
| America Medical And Health Systemreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥45m |
| America Medical And Health Systemreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥28m |
| America Medical And Health Systemreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥7.6bn |
| America Medical And Health Systemreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥7.6bn |
| America Medical And Health Systemreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥10m |
| America Medical And Health Systemreportable segment | segment assets | at 2022-03-31 | ¥3.7bn |
| America Medical And Health Systemreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥221m |
| Asia And Oceania Measuring Instrumentsreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥869m |
| Asia And Oceania Measuring Instrumentsreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥106m |
| Asia And Oceania Measuring Instrumentsreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥7.0bn |
| Asia And Oceania Measuring Instrumentsreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥4.1bn |
| Asia And Oceania Measuring Instrumentsreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥2.9bn |
| Asia And Oceania Measuring Instrumentsreportable segment | segment assets | at 2022-03-31 | ¥6.3bn |
| Asia And Oceania Measuring Instrumentsreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥428m |
| Asia And Oceania Medical And Health Systemreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥62m |
| Asia And Oceania Medical And Health Systemreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥181m |
| Asia And Oceania Medical And Health Systemreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥7.8bn |
| Asia And Oceania Medical And Health Systemreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥533m |
| Asia And Oceania Medical And Health Systemreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥7.3bn |
| Asia And Oceania Medical And Health Systemreportable segment | segment assets | at 2022-03-31 | ¥4.0bn |
| Asia And Oceania Medical And Health Systemreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥378m |
| Europe Measuring Instrumentsreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥3m |
| Europe Measuring Instrumentsreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥13m |
| Europe Measuring Instrumentsreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥869m |
| Europe Measuring Instrumentsreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥868m |
| Europe Measuring Instrumentsreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥0 |
| Europe Measuring Instrumentsreportable segment | segment assets | at 2022-03-31 | ¥776m |
| Europe Measuring Instrumentsreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥61m |
| Europe Medical And Health Systemreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥48m |
| Europe Medical And Health Systemreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥85m |
| Europe Medical And Health Systemreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥7.8bn |
| Europe Medical And Health Systemreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥7.8bn |
| Europe Medical And Health Systemreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥5m |
| Europe Medical And Health Systemreportable segment | segment assets | at 2022-03-31 | ¥5.3bn |
| Europe Medical And Health Systemreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥1.1bn |
| Japan Measuring Instrumentsreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥1.4bn |
| Japan Measuring Instrumentsreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥955m |
| Japan Measuring Instrumentsreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥24.8bn |
| Japan Measuring Instrumentsreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥21.5bn |
| Japan Measuring Instrumentsreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥3.4bn |
| Japan Measuring Instrumentsreportable segment | segment assets | at 2022-03-31 | ¥38.2bn |
| Japan Measuring Instrumentsreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥2.7bn |
| Japan Medical And Health Systemreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥178m |
| Japan Medical And Health Systemreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥164m |
| Japan Medical And Health Systemreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥15.2bn |
| Japan Medical And Health Systemreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥5.6bn |
| Japan Medical And Health Systemreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥9.7bn |
| Japan Medical And Health Systemreportable segment | segment assets | at 2022-03-31 | ¥7.1bn |
| Japan Medical And Health Systemreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥2.2bn |
| Measurement Weighing Instruments Businessesreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥2.3bn |
| Measurement Weighing Instruments Businessesreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥1.1bn |
| Measurement Weighing Instruments Businessesreportable segment | employees | at 2022-03-31 | 1268 pure |
| Measurement Weighing Instruments Businessesreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥36.7bn |
| Measurement Weighing Instruments Businessesreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥30.2bn |
| Measurement Weighing Instruments Businessesreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥6.5bn |
| Measurement Weighing Instruments Businessesreportable segment | segment assets | at 2022-03-31 | ¥48.7bn |
| Measurement Weighing Instruments Businessesreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥3.5bn |
| Medical Healthcare Instruments Businessesreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥334m |
| Medical Healthcare Instruments Businessesreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥459m |
| Medical Healthcare Instruments Businessesreportable segment | employees | at 2022-03-31 | 1266 pure |
| Medical Healthcare Instruments Businessesreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥38.5bn |
| Medical Healthcare Instruments Businessesreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥21.5bn |
| Medical Healthcare Instruments Businessesreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥16.9bn |
| Medical Healthcare Instruments Businessesreportable segment | segment assets | at 2022-03-31 | ¥20.1bn |
| Medical Healthcare Instruments Businessesreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥3.9bn |
| Reconciling Itemsreconciling | capex | 2020-04-01 → 2021-03-31 | ¥65m |
| Reconciling Itemsreconciling | depreciation | 2020-04-01 → 2021-03-31 | ¥47m |
| Reconciling Itemsreconciling | revenue | 2020-04-01 → 2021-03-31 | −¥21.3bn |
| Reconciling Itemsreconciling | revenue intersegment | 2020-04-01 → 2021-03-31 | −¥21.3bn |
| Reconciling Itemsreconciling | segment assets | at 2021-03-31 | −¥9.7bn |
| Reconciling Itemsreconciling | segment profit | 2020-04-01 → 2021-03-31 | −¥1.9bn |
| America Measuring Instrumentsreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥6m |
| America Measuring Instrumentsreportable segment | depreciation | 2020-04-01 → 2021-03-31 | ¥41m |
| America Measuring Instrumentsreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥3.3bn |
| America Measuring Instrumentsreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥3.2bn |
| America Measuring Instrumentsreportable segment | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥151m |
| America Measuring Instrumentsreportable segment | segment assets | at 2021-03-31 | ¥2.3bn |
| America Measuring Instrumentsreportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥201m |
| America Medical And Health Systemreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥6m |
| America Medical And Health Systemreportable segment | depreciation | 2020-04-01 → 2021-03-31 | ¥30m |
| America Medical And Health Systemreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥7.6bn |
| America Medical And Health Systemreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥7.6bn |
| America Medical And Health Systemreportable segment | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥3m |
| America Medical And Health Systemreportable segment | segment assets | at 2021-03-31 | ¥3.2bn |
| America Medical And Health Systemreportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥346m |
| Asia And Oceania Measuring Instrumentsreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥67m |
| Asia And Oceania Measuring Instrumentsreportable segment | depreciation | 2020-04-01 → 2021-03-31 | ¥78m |
| Asia And Oceania Measuring Instrumentsreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥5.6bn |
| Asia And Oceania Measuring Instrumentsreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥3.3bn |
| Asia And Oceania Measuring Instrumentsreportable segment | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥2.3bn |
| Asia And Oceania Measuring Instrumentsreportable segment | segment assets | at 2021-03-31 | ¥5.1bn |
| Asia And Oceania Measuring Instrumentsreportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥197m |
| Asia And Oceania Medical And Health Systemreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥53m |
| Asia And Oceania Medical And Health Systemreportable segment | depreciation | 2020-04-01 → 2021-03-31 | ¥166m |
| Asia And Oceania Medical And Health Systemreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥7.3bn |
| Asia And Oceania Medical And Health Systemreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥379m |
| Asia And Oceania Medical And Health Systemreportable segment | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥6.9bn |
| Asia And Oceania Medical And Health Systemreportable segment | segment assets | at 2021-03-31 | ¥3.6bn |
| Asia And Oceania Medical And Health Systemreportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥306m |
| Europe Measuring Instrumentsreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥16m |
| Europe Measuring Instrumentsreportable segment | depreciation | 2020-04-01 → 2021-03-31 | ¥20m |
| Europe Measuring Instrumentsreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥844m |
| Europe Measuring Instrumentsreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥802m |
| Europe Measuring Instrumentsreportable segment | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥41m |
| Europe Measuring Instrumentsreportable segment | segment assets | at 2021-03-31 | ¥809m |
| Europe Measuring Instrumentsreportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥25m |
| Europe Medical And Health Systemreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥41m |
| Europe Medical And Health Systemreportable segment | depreciation | 2020-04-01 → 2021-03-31 | ¥118m |
| Europe Medical And Health Systemreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥7.4bn |
| Europe Medical And Health Systemreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥7.3bn |
| Europe Medical And Health Systemreportable segment | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥5m |
| Europe Medical And Health Systemreportable segment | segment assets | at 2021-03-31 | ¥5.1bn |
| Europe Medical And Health Systemreportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥943m |
| Japan Measuring Instrumentsreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥2.0bn |
| Japan Measuring Instrumentsreportable segment | depreciation | 2020-04-01 → 2021-03-31 | ¥987m |
| Japan Measuring Instrumentsreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥21.8bn |
| Japan Measuring Instrumentsreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥19.3bn |
| Japan Measuring Instrumentsreportable segment | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥2.5bn |
| Japan Measuring Instrumentsreportable segment | segment assets | at 2021-03-31 | ¥36.4bn |
| Japan Measuring Instrumentsreportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥1.3bn |
| Japan Medical And Health Systemreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥149m |
| Japan Medical And Health Systemreportable segment | depreciation | 2020-04-01 → 2021-03-31 | ¥174m |
| Japan Medical And Health Systemreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥15.8bn |
| Japan Medical And Health Systemreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥6.4bn |
| Japan Medical And Health Systemreportable segment | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥9.3bn |
| Japan Medical And Health Systemreportable segment | segment assets | at 2021-03-31 | ¥7.4bn |
| Japan Medical And Health Systemreportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥3.0bn |
| Measurement Weighing Instruments Businessesreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥2.0bn |
| Measurement Weighing Instruments Businessesreportable segment | depreciation | 2020-04-01 → 2021-03-31 | ¥1.1bn |
| Measurement Weighing Instruments Businessesreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥31.7bn |
| Measurement Weighing Instruments Businessesreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥26.7bn |
| Measurement Weighing Instruments Businessesreportable segment | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥5.0bn |
| Measurement Weighing Instruments Businessesreportable segment | segment assets | at 2021-03-31 | ¥44.6bn |
| Measurement Weighing Instruments Businessesreportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥1.7bn |
| Medical Healthcare Instruments Businessesreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥250m |
| Medical Healthcare Instruments Businessesreportable segment | depreciation | 2020-04-01 → 2021-03-31 | ¥489m |
| Medical Healthcare Instruments Businessesreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥38.0bn |
| Medical Healthcare Instruments Businessesreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥21.8bn |
| Medical Healthcare Instruments Businessesreportable segment | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥16.2bn |
| Medical Healthcare Instruments Businessesreportable segment | segment assets | at 2021-03-31 | ¥19.2bn |
| Medical Healthcare Instruments Businessesreportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥4.6bn |
| Measurement Weighing Instruments Businessesreportable segment | employees | at 2022-03-31 | 512 pure |
| Medical Healthcare Instruments Businessesreportable segment | employees | at 2022-03-31 | 174 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,900
| Item | Context | Value | Unit |
|---|---|---|---|
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 189 | |
| Total shareholder return | Prior4YearInstant_NonConsolidatedMember | 1.486 | |
| Total shareholder return | Prior3YearInstant_NonConsolidatedMember | 1.756 | |
| Total shareholder return | Prior2YearInstant_NonConsolidatedMember | 1.530 | |
| Total shareholder return | Prior1YearInstant_NonConsolidatedMember | 2.922 | |
| Total shareholder return | CurrentYearInstant_NonConsolidatedMember | 2.366 | |
| Total return on share price index | Prior4YearInstant_NonConsolidatedMember | 1.159 | |
| Total return on share price index | Prior3YearInstant_NonConsolidatedMember | 1.100 | |
| Total return on share price index | Prior2YearInstant_NonConsolidatedMember | 0.996 | |
| Total return on share price index | Prior1YearInstant_NonConsolidatedMember | 1.415 | |
| Total return on share price index | CurrentYearInstant_NonConsolidatedMember | 1.443 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E02344-000MeasurementWeighingInstrumentsBusinessesReportableSegmentsMember | 1268 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E02344-000MeasurementWeighingInstrumentsBusinessesReportableSegmentsMember | 208 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E02344-000MedicalHealthcareInstrumentsBusinessesReportableSegmentsMember | 1266 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E02344-000MedicalHealthcareInstrumentsBusinessesReportableSegmentsMember | 93 | |
| Number of employees | CurrentYearInstant_CorporateSharedMember | 57 | |
| Average number of temporary workers | CurrentYearInstant_CorporateSharedMember | 15 | |
| Number of employees | CurrentYearInstant | 2591 | |
| Average number of temporary workers | CurrentYearInstant | 316 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 743 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 189 | |
| Average age years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 42.27 | |
| Average length of service years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 15.52 | |
| Average annual salary information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 7366447 | JPY |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E02344-000MeasurementWeighingInstrumentsBusinessesReportableSegmentsMember | 512 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E02344-000MeasurementWeighingInstrumentsBusinessesReportableSegmentsMember | 117 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E02344-000MedicalHealthcareInstrumentsBusinessesReportableSegmentsMember | 174 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E02344-000MedicalHealthcareInstrumentsBusinessesReportableSegmentsMember | 57 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_CorporateSharedMember | 57 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember_CorporateSharedMember | 15 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 743 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 189 | |
| Research and development expenses research and development activities | CurrentYearDuration | 4874000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E02344-000MeasurementWeighingInstrumentsBusinessesReportableSegmentsMember | 3943000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E02344-000MedicalHealthcareInstrumentsBusinessesReportableSegmentsMember | 931000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration | 2189000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E02344-000MeasuringInstrumentsReportableSegmentsMember | 1917000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E02344-000MedicalHealthcareInstrumentsBusinessesReportableSegmentsMember | 258000000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 22601400 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 27845208 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 22601400 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 27845208 | |
| Number of shares constituting one unit | CurrentYearInstant_OrdinaryShareMember | 100 | |
| Number of shareholders national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shareholders financial institutions | CurrentYearInstant_OrdinaryShareMember | 20 | |
| Number of shareholders financial service providers | CurrentYearInstant_OrdinaryShareMember | 34 | |
| Number of shareholders other corporations | CurrentYearInstant_OrdinaryShareMember | 69 | |
| Number of shareholders foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 97 | |
| Number of shareholders foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 22 | |
| Number of shareholders individuals and others | CurrentYearInstant_OrdinaryShareMember | 6528 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |